Rivastigmine in vascular dementia

被引：20

作者：

Moretti, R ^{[1
]}

Torre, P ^{[1
]}

Antonello, RM ^{[1
]}

Cazzato, G ^{[1
]}

Bava, A ^{[1
]}

机构：

[1] Univ Trieste, Osped Cattinara, Ist Clin Neurol, I-34149 Trieste, Italy

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2004年 / 5卷 / 06期

关键词：

behaviour; cholinesterase inhibition; executive function; rivastigmine; vascular dementia;

D O I：

10.1517/14656566.5.6.1399

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Patients with vascular dementia (VaD) show cholinergic deficits that may result in characteristic clinical syndromes for different subtypes of the condition. Subcortical VaD is characterised by executive dysfunction and behavioural problems, reflecting deterioration of the frontal lobe. Based on limited open-labelled controlled studies of rivastigmine in VaD, this article aims to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), has any effects on the typical symptoms of subcortical VaD. Long-term rivastigmine treatment is safe and effective. Improvements in domains that characterise subcortical VaD were observed, indicating that rivastigmine may have provided targeted treatment in areas of the brain that are particularly affected in this patient population. A large, double-blind study of rivastigmine in patients with VaD is clearly warranted.

引用

页码：1399 / 1410

页数：12

共 88 条

[21] Emerging therapies for vascular dementia and vascular cognitive impairment [J].

Erkinjuntti, T ;

Román, G ;

Gauthier, S ;

Feldman, H ;

Rockwood, K .

STROKE, 2004, 35 (04) :1010-1017

[22] Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial [J].

Erkinjuntti, T ;

Kurz, A ;

Gauthier, S ;

Bullock, R ;

Lilienfeld, S ;

Damaraju, CV .

LANCET, 2002, 359 (9314) :1283-1290

[23]

ERKINJUNTTI T, 2001, 53 ANN M AM AC NEUR

[24]

ERKINJUTTI T, 1997, INT PSYCHOGERIATR, V9, P77

[25]

FRAMPTON M, 2003, COCHRANE LIB

[26] Selective inhibitors of butyrylcholinesterase - A valid alternative for therapy of Alzheimer's disease? [J].

Giacobini, E .

DRUGS & AGING, 2001, 18 (12) :891-898

[27] Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit [J].

Giacobini, E ;

Spiegel, R ;

Enz, A ;

Veroff, AE ;

Cutler, NR .

JOURNAL OF NEURAL TRANSMISSION, 2002, 109 (7-8) :1053-1065

[28] THE NEUROCHEMISTRY OF VASCULAR DEMENTIA [J].

GOTTFRIES, CG ;

BLENNOW, K ;

KARLSSON, I ;

WALLIN, A .

DEMENTIA, 1994, 5 (3-4) :163-167

[29] Long-term use of rivastigmine in patients with dementia with Lewy bodies: An open-label trial [J].

Grace, J ;

Daniel, S ;

Stevens, T ;

Shankar, KK ;

Walker, Z ;

Byrne, EJ ;

Butler, S ;

Wilkinson, D ;

Woolford, J ;

Waite, J ;

McKeith, IG .

INTERNATIONAL PSYCHOGERIATRICS, 2001, 13 (02) :199-205

[30]

GROSSBERG G, 2001, INT PSYCHOGERIATR S, V13, P237

← 1 2 3 4 5 6 7 8 9 →